메뉴 건너뛰기




Volumn 25, Issue 4, 2015, Pages 976-981

1,2,3,9b-Tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 2: Identification of BTA9881 as a preclinical candidate

Author keywords

Antiviral; Respiratory syncytial virus; Synthesis

Indexed keywords

BTA 9881; UNCLASSIFIED DRUG; VIRUS FUSION INHIBITOR;

EID: 84964282399     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2014.11.024     Document Type: Article
Times cited : (14)

References (18)
  • 3
    • 84964216252 scopus 로고    scopus 로고
    • U.S Food and Drug Administration. Palivizumab Product Approval Information - Licensing Action
    • U.S Food and Drug Administration. Palivizumab Product Approval Information - Licensing Action. www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm093366.htm.


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.